Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality around the world. Brain metastasis (BM) is seen in up to 20-40% patients with NSCLC [1,2]. Patients with EGFR mutation have a higher likelihood of BM because of prolonged survival by EGFR tyrosine kinase inhibitors (EGFR-TKIs) [3 –5]. Further, whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and surgical excision are options for local control, and each shows different treatment benefit in selected subgroups [6].

Source: Lung Cancer - October 10, 2019 Category: Cancer & Oncology Authors: Chia-I Shen, Hsu-Ching Huang, Chi-Lu Chiang, Yung-Hung Luo, Tsu-Hui Shiao, Chao-Hua Chiu Source Type: research